Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/29/2025 13:58 PDT] Royalty Pharma plc (NASDAQ:RPRX), Up By 100% ($30.85) From $30.85 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/15/2025 07:44 PDT] RPRX Expected to Trade Up After Bullish Patterns Develop
• [04/09/2025 07:19 PDT] RPRX Expected to Trade Up After Bullish Patterns Develop
• [04/07/2025 10:29 PDT] Royalty Pharma plc (NASDAQ:RPRX), Down By 100% ($31.58) From $31.58 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/01/2025 07:35 PDT] RPRX Expected to Trade Up After Bullish Patterns Develop
• [03/31/2025 07:47 PDT] RPRX Expected to Trade Up After Bullish Patterns Develop
• [03/28/2025 07:29 PDT] RPRX Expected to Trade Down After Bearish Patterns Develop
• [03/13/2025 07:12 PDT] RPRX Expected to Trade Up After Bullish Patterns Develop